Crispr Therapeutics provides updates on zugo-cel

CRISPR Therapeutics (CRSP) provided updates on zugocaptagene geleucel, zugo-cel, formerly known as CTX112, its investigational allogeneic CAR T targeting CD19, in development for autoimmune disease and hematologic malignancies. Zugo-cel, targeting CD19, is in an ongoing Phase 1 basket trial in autoimmune rheumatologic diseases. As of the data cut-off on December 17, 2025, four patients have been treated at a dose of 100 million cells and followed for at least 28 days post-infusion: Zugo-cel cell expansion is comparable to that observed at the same dose in patients in the ongoing B-cell lymphomas trial. Rapid and deep B-cell depletion in the periphery was observed within the first 1-2 days and maintained over the first month of treatment. All patients demonstrated significant clinical improvement at the Day 28 assessment. The first patient with SLE, refractory to 9 prior therapies with a baseline Systemic Lupus Erythematosus Disease Activity Index 2000 score of 8, has maintained drug-free DORIS clinical remission through Month 6 following CAR T therapy. Treatment has been well-tolerated. Positive clinical data generated to date support the advancement of zugo-cel into the Phase 2 portion of the ongoing Phase 1/2 trial in patients with CD19-positive B-cell malignancies. As of the data cut-off of November 20, 2025, 10 patients with R/R LBCL have been treated at the RP2D of 600 million cell dose and have had at least one month of follow-up, with the following observations: An overall response rate of 90% and a complete response rate of 70% were observed, including a complete response in a patient who relapsed following autologous CAR T cell therapy. Among patients who have completed 12-months of follow-up, 67% remained in CR at the 12-month evaluation. Peak mean CAR T cell expansion of approximately 1,700 cells/microL was observed at the RP2D, representing approximately a four-fold higher expansion compared with patients receiving 300 million cells.